{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:55:23Z","timestamp":1781758523959,"version":"3.54.5"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["Id. 21840"],"award-info":[{"award-number":["Id. 21840"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Accurately predicting pathological complete response (pCR) after primary systemic therapy (PST) in breast cancer remains a clinical challenge. This study compares the diagnostic performance of ultrasound (US) and Fluorodeoxyglucose positron emission tomography\/magnetic resonance imaging ([18F]FDG PET\/MRI) in predicting breast-pCR following PST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter analysis included 143 patients: 54 node-positive patients from San Raffaele Hospital, who underwent an additional [18F]FDG PET\/MRI within a prospective trial (ClinicalTrials.gov ID: NCT04826211) and 89 cases retrospectively retrieved from the database of Heidelberg Hospital, irrespectively of nodal status at diagnosis. In US, breast clinical complete response (breast cCR) was defined as a tumor size of 0\u00a0mm or no sign of tumor in the breast; in [18F]FDG PET\/MRI, as the absence of significant [18F]FDG uptake on PET images and contrast-enhancement on MRI. Diagnostic accuracy was assessed across PET only, MRI only, combined PET\/MRI (PET or MRI positive), and concordant PET\/MRI (both positive). Subgroup analyses explored associations of breast cCR with tumor molecular subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>[18F]FDG PET\/MRI showed a sensitivity of 62% (95% CI 42%-81%) and a specificity of 67% (95% CI 46%-83%), whereas ultrasound showed a sensitivity of 59% (95% CI 44%-73%) and a specificity of 62% (95% CI 46%-77%) in detecting breast response to PST. No significant difference was observed between [18F]FDG PET\/MRI and US in terms of sensitivity (62.9%vs59.1%, p=0.93) and specificity (66.6%vs62.2%, p=0.94) in detecting response to PST. Exploratory subgroup analysis suggested variation in sensitivity: US showed a sensitivity of 73% (95% CI 0.45-0.92) in triple-negative tumors and 50% (95% CI 16%-84%) in HER2-positive tumors, while [18F]FDG PET\/MRI demonstrated a sensitivity of 77% (95% CI 46%-95%) in Luminal B cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>[18F]FDG PET\/MRI and US showed comparable performance in diagnostic accuracy of breast pCR following PST, with varying effectiveness across tumor subtypes. Further research should focus on multimodal imaging strategies integrated with clinical and molecular data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1845216","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:36:36Z","timestamp":1781757396000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET\/MRI in breast response assessment"],"prefix":"10.3389","volume":"16","author":[{"given":"Rosa","family":"Di Micco","sequence":"first","affiliation":[{"name":"Breast Surgery Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin","family":"Saracoglu","sequence":"additional","affiliation":[{"name":"Breast Surgery Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Pfob","sequence":"additional","affiliation":[{"name":"Breast Centre Heidelberg, Klinik St. Elisabeth","place":["Heidelberg, Germany"]},{"name":"Department of Obstetrics and Gynecology, Breast Cancer Center, Heidelberg University Hospital","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Canevari","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gallivanone","sequence":"additional","affiliation":[{"name":"Institute of Bioimaging and Molecular Physiology, National Research Council","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidija","family":"Antunovic","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Gelardi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Vita-Salute San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Scifo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Neri","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Losio","sequence":"additional","affiliation":[{"name":"Breast Radiology Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Venturini","sequence":"additional","affiliation":[{"name":"Breast Radiology Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Della Vecchia","sequence":"additional","affiliation":[{"name":"Breast Radiology Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goffredo","family":"Ferrarese","sequence":"additional","affiliation":[{"name":"Breast Radiology Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Rotmensz","sequence":"additional","affiliation":[{"name":"Breast Surgery Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Zuber","sequence":"additional","affiliation":[{"name":"Breast Surgery Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Baleri","sequence":"additional","affiliation":[{"name":"Breast Surgery Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cisternino","sequence":"additional","affiliation":[{"name":"Breast Surgery Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Paola","family":"Corona","sequence":"additional","affiliation":[{"name":"Breast Surgery Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Calabretto","sequence":"additional","affiliation":[{"name":"Breast Surgery Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rampa","sequence":"additional","affiliation":[{"name":"Breast Surgery Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Licata","sequence":"additional","affiliation":[{"name":"Oncology Department, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Viale","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Vita-Salute San Raffaele","place":["Milan, Italy"]},{"name":"Breast Radiology Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Zambelli","sequence":"additional","affiliation":[{"name":"Oncology Department, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Sassi","sequence":"additional","affiliation":[{"name":"Pathology Department, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Vita-Salute San Raffaele","place":["Milan, Italy"]},{"name":"Oncology Department, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Panizza","sequence":"additional","affiliation":[{"name":"Breast Radiology Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]},{"name":"Universit\u00e0 Vita-Salute San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Heil","sequence":"additional","affiliation":[{"name":"Breast Centre Heidelberg, Klinik St. Elisabeth","place":["Heidelberg, Germany"]},{"name":"Department of Obstetrics and Gynecology, Breast Cancer Center, Heidelberg University Hospital","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreste Davide","family":"Gentilini","sequence":"additional","affiliation":[{"name":"Breast Surgery Unit, IRCCS Ospedale San Raffaele","place":["Milan, Italy"]},{"name":"Universit\u00e0 Vita-Salute San Raffaele","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102569","article-title":"Breast cancer\u2014epidemiology, classification, pathogenesis and treatment (review of literature)","volume":"14","author":"Smolarz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7016","article-title":"The evolving role of neoadjuvant therapy for operable breast cancer","volume":"20","author":"Spring","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx773","article-title":"Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study","volume":"29","author":"Swain","year":"2018","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000197714.14318.6f","article-title":"Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumour size in patients treated with neoadjuvant chemotherapy","volume":"243","author":"Chagpar","year":"2006","journal-title":"Ann Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143521","article-title":"Assessment and prediction of response to neoadjuvant chemotherapy in breast cancer: a comparison of imaging modalities and future perspectives","volume":"13","author":"Romeo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.388","article-title":"Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk","volume":"307","author":"Berg","year":"2012","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020401","article-title":"Prediction of primary tumour and axillary lymph node response to neoadjuvant chemo(targeted) therapy with dedicated breast [18F]FDG PET\/MRI in breast cancer","volume":"15","author":"de Mooij","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00577-5","article-title":"Clinical advances in PET\/MRI for breast cancer","volume":"23","author":"Fowler","year":"2022","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143571","article-title":"PET\/MRI for staging the axilla in breast cancer: current evidence and the rationale for SNB vs. PET\/MRI trials","volume":"13","author":"Di Micco","year":"2021","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00613-1","article-title":"Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial","volume":"23","author":"Kuerer","year":"2022","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14551-8","article-title":"Minimally invasive breast biopsy after neoadjuvant systemic treatment to identify breast cancer patients with residual disease for extended neoadjuvant treatment: a new concept","volume":"31","author":"Pfob","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02439","article-title":"Intelligent vacuum-assisted biopsy to identify breast cancer patients with pathologic complete response (ypT0 and ypN0) after neoadjuvant systemic treatment for omission of breast and axillary surgery","volume":"40","author":"Pfob","year":"2022","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1186\/s12885-018-4760-4","article-title":"RESPONDER \u2013 diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial","volume":"18","author":"Heil","year":"2018","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"h5527","DOI":"10.1148\/radiol.2015151516","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies","volume":"351","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115519","article-title":"18F]FDG PET\/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial","volume":"224","author":"Di Micco","year":"2025","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.10.4889","article-title":"Application of MR mammography beyond local staging: is there a potential to accurately assess axillary lymph nodes? Evaluation of an extended protocol in an initial prospective study","volume":"196","author":"Baltzer","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.07.034","article-title":"Detection of extra-axillary lymph node involvement with FDG PET\/CT in patients with stage II-III breast cancer","volume":"46","author":"Aukema","year":"2010","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3823-0","article-title":"Added value of dedicated axillary hybrid 18F-FDG PET\/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study","volume":"45","author":"van Nijnatten","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs528","article-title":"Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy","volume":"105","author":"Marinovich","year":"2013","journal-title":"J Natl Cancer Institute"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s13244-013-0219-y","article-title":"The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review","volume":"4","author":"Lobbes","year":"2013","journal-title":"Insights into Imaging"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4741.2010.00927.x","article-title":"Role of fusion of prone FDG-PET and magnetic resonance imaging of the breasts in the evaluation of breast cancer","volume":"16","author":"Moy","year":"2010","journal-title":"Breast J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1148\/radiol.2016151155","article-title":"Comparison of whole-body (18)F FDG PET\/MR imaging and whole-body (18)F FDG PET\/CT in terms of lesion detection and radiation dose in patients with breast cancer","volume":"281","author":"Melsaether","year":"2016","journal-title":"Radiology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-023-00953-y","article-title":"The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis","volume":"13","author":"de Mooij","year":"2023","journal-title":"EJNMMI Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.bjc.6605427","article-title":"Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer","volume":"102","author":"Dose-Schwarz","year":"2010","journal-title":"Br J Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1148\/radiol.12111177","article-title":"Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET\/CT and dynamic contrast-enhanced MR imaging\u2014prospective assessment","volume":"263","author":"Tateishi","year":"2012","journal-title":"Radiology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.annonc.2019.10.012","article-title":"Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges","volume":"31","author":"Heil","year":"2020","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.01.219","article-title":"Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: time trend, imaging staging power and nodal downstaging according to molecular subtype","volume":"45","author":"Di Micco","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103806","article-title":"Role of [18F]FDG PET\/CT in patients with invasive breast carcinoma of no special type: literature review and comparison between guidelines","volume":"78","author":"Groheux","year":"2024","journal-title":"Breast"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115607","article-title":"Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients - results from the prospective AXSANA registry trial","volume":"226","author":"Di Micco","year":"2025","journal-title":"Eur J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2023.07.010","article-title":"Value of ultrasound in assessing response to neoadjuvant chemotherapy in breast cancer","volume":"78","author":"Lim","year":"2023","journal-title":"Clin Radiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/8756479320964102","article-title":"Breast ultrasound versus MRI in prediction of pathologic complete response to neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis","volume":"37","author":"Sanei Sistani","year":"2021","journal-title":"J Diagn Med Sonogr"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15205088","article-title":"Simultaneous 18F-FDG PET\/MRI radiomics and machine learning analysis of the primary breast tumor for the preoperative prediction of axillary lymph node status in breast cancer","volume":"15","author":"Romeo","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1845216\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:36:44Z","timestamp":1781757404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1845216\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1845216"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1845216","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1845216"}}